This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Kangstem Biotech Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Mijin Kim: Innovator in Stem Cell Technology
Introduction
Mijin Kim is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of stem cell research, particularly in the production of umbilical cord blood-derived stem cells. His innovative approach has the potential to enhance the efficacy of stem cell therapies.
Latest Patents
Mijin Kim holds a patent for a groundbreaking method titled "METHOD FOR PRODUCING UMBILICAL CORD BLOOD-DERIVED STEM CELL WITH ENHANCED EFFICACY." This patent reflects his commitment to advancing medical science and improving treatment options for patients.
Career Highlights
Currently, Mijin Kim is associated with Kangstem Biotech Co., Ltd., a company dedicated to pioneering advancements in biotechnology. His work at Kangstem Biotech has positioned him as a key player in the development of innovative stem cell therapies.
Collaborations
Mijin Kim collaborates with talented professionals in his field, including Jong Chan Ahn and Seunghee Lee. Their combined expertise fosters a dynamic environment for research and development.
Conclusion
Mijin Kim's contributions to stem cell technology exemplify the impact of innovative thinking in the medical field. His work continues to inspire advancements that may lead to improved health outcomes for many individuals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile